Arvinas Holding Company (ARVN) AI Stock Analysis

• Market Cap: $535.03M
• Dividend Yield: N/A
• Average Volume (3M): 2.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: -39.92%
• EPS Growth: 7.38%
• Country: US
• Employees: 430
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 1.14
• Shares Outstanding: 72,991,390
• 10 Day Avg. Volume: 2,015,246
• 30 Day Avg. Volume: 2,784,283
• PEG Ratio: -0.16
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.53
• Price Target Upside: 107.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 19

• Rating: 49 Neutral
• Price Target: $7.00 ▲(0.00%Upside)

Arvinas's overall stock score reflects strong revenue growth and positive strategic developments from recent earnings calls, but is weighed down by ongoing profitability challenges and mixed technical indicators. The company's negative valuation metrics further contribute to a cautious outlook.

Positive Factors

Efficacy and Safety

Vepdegestrant achieved a median progression-free survival (PFS) of 5.0 months vs 2.1 months with fulvestrant, placing vepdeg ahead of other oral SERDs in the competitive landscape.

Market Positioning

Pfizer's strong presence in breast cancer is expected to help drive the adoption of vepdegestrant.

Tolerability

Low rates of adverse events could meaningfully influence physician choice, favoring vepdegestrant over other treatments.

Negative Factors

Commercialization Strategy

Co-commercialization may be less appealing for both companies, given the relatively small target patient population.

Market Competition

As a monotherapy, the drug may face competition from other treatments, potentially relegating it to a later line of therapy.

Partnership Uncertainty

There is expected volatility in ARVN shares as discussions continue regarding the future of the Pfizer partnership.

Arvinas Holding Company Business Overview & Revenue Model

Company Description

Arvinas Holding Company (ARVN) is a biopharmaceutical company engaged in the research and development of therapeutics aimed at degrading disease-causing proteins. The company operates in the healthcare sector, focusing on creating innovative protein degradation therapies for the treatment of cancers and other serious diseases. Arvinas leverages its proprietary PROTAC (PROteolysis TArgeting Chimeras) technology platform to develop small molecule therapies that harness the body's natural protein disposal system to selectively degrade and eliminate unwanted proteins.

How the Company Makes Money

Arvinas makes money primarily through the development and commercialization of its proprietary therapeutics. The company generates revenue from collaboration and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties. These partnerships enable Arvinas to leverage its PROTAC technology across a broader range of therapeutic areas while sharing development costs and risks. Additionally, as its drug candidates progress through clinical trials and receive regulatory approval, Arvinas anticipates generating revenue from the sales of its proprietary drugs. Key factors contributing to its earnings include successful clinical trial outcomes, strategic partnerships, and the eventual commercialization of its drug candidates.

Arvinas Holding Company Financial Statement Overview

Summary

Arvinas shows strong revenue growth but is challenged by unprofitability and negative cash flows. The balance sheet is stable with a strong equity base, but operational efficiencies need improvement to sustain long-term growth.

Income Statement

Arvinas Holding Company has shown a significant increase in total revenue with a TTM revenue of $426.9M compared to $263.4M in the previous year, indicating strong growth. However, the company remains unprofitable with negative EBIT and net income, reflecting challenges in managing operational costs and achieving profitability. The gross profit margin is high, but the negative net profit margin highlights the significant expenses outweighing revenues.

Balance Sheet

The balance sheet is relatively stable with a strong equity base and a low debt-to-equity ratio, suggesting prudent financial management. The company maintains a high level of cash and equivalents, which provides a buffer against financial uncertainty. The equity ratio indicates a solid capital structure, which is positive for long-term stability.

Cash Flow

The cash flow statement reveals challenges with negative operating and free cash flows, indicating potential difficulties in sustaining operations without additional financing. Despite this, the company has managed to maintain liquidity through investing activities. The negative free cash flow growth rate suggests that the company is not yet generating sufficient cash from its operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
426.90M	263.40M	78.50M	131.40M	46.70M	21.80M
	Gross Profit
423.60M	256.80M	78.50M	123.20M	40.70M	21.80M
	EBIT
-95.60M	-250.20M	-401.50M	-263.20M	-195.30M	-124.86M
	EBITDA
-91.00M	-250.20M	-394.80M	-256.90M	-183.60M	-117.60M
	Net Income Common Stockholders
-46.60M	-198.90M	-367.30M	-271.90M	-183.20M	-111.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
954.30M	1.04B	1.26B	1.21B	1.50B	688.53M
	Total Assets
1.00B	1.09B	1.30B	1.27B	1.58B	717.37M
	Total Debt
10.50M	9.70M	3.20M	5.50M	5.00M	4.04M
	Net Debt
-70.50M	-90.80M	-308.50M	-75.80M	-103.30M	-584.33M
	Total Liabilities
341.00M	529.70M	644.60M	703.90M	799.90M	75.11M
	Stockholders Equity
660.10M	561.70M	660.00M	564.90M	781.70M	642.26M
Cash Flow		Free Cash Flow
-252.80M	-261.10M	-350.70M	-280.30M	554.70M	-96.20M
	Operating Cash Flow
-250.70M	-259.30M	-347.80M	-273.50M	559.40M	-89.76M
	Investing Cash Flow
232.00M	34.70M	203.50M	242.80M	-1.31B	164.25M
	Financing Cash Flow
6.20M	7.90M	374.70M	4.70M	278.60M	504.67M

Arvinas Holding Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Negative. The current price of 7 is above the 20-day moving average (MA) of 6.70, below the 50-day MA of 7.34, and below the 200-day MA of 18.02, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 46.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARVN.

Arvinas Holding Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	73 Outperform	$923.97M	68.21	33.47%	―	29.77%	―
PRTC	64 Neutral	$448.64M	8.94	11.96%	―	43.67%	―
IMTX	59 Neutral	$730.52M	53.85	-4.52%	―	92.31%	78.17%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
ARVN	49 Neutral	$535.03M	―	-35.41%	―	-39.92%	7.38%
OPT	39 Underperform	$480.08M	―		―	-25.10%	-7.06%

Arvinas Holding Company Corporate Events

Arvinas and Pfizer Announce Phase 3 Trial Results

On May 31, 2025, Arvinas, Inc. and Pfizer announced detailed results from their Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant as a monotherapy for ER+/HER2- advanced or metastatic breast cancer. The trial demonstrated a significant improvement in progression-free survival among patients with ESR1 mutations, with vepdegestrant reducing the risk of disease progression or death by 43% compared to fulvestrant. Despite not reaching statistical significance in the intent-to-treat population, the results suggest vepdegestrant’s potential as a best-in-class treatment option. The companies plan to submit a New Drug Application to the FDA in the latter half of 2025, indicating a significant step towards regulatory approval and potential market introduction.

The most recent analyst rating on (ARVN) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.

Arvinas Showcases Promising Preclinical Data at AACR

On April 28, 2025, Arvinas presented preclinical data at the AACR annual meeting in Chicago, showcasing the investigational PROTAC BCL6 degrader, ARV-393. The studies demonstrated synergistic antitumor activity and complete tumor regressions when combined with standard chemotherapy, biologics, and investigational small molecule inhibitors in models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma. These findings highlight the potential for ARV-393 in combination therapies for lymphoma, supporting further evaluation in clinical settings.

Arvinas Holding Company Unveils Promising ARV-102 Trial Results

On April 4, 2025, Arvinas, Inc. presented promising data from the first-in-human clinical trial of ARV-102, an investigational PROTAC LRRK2 degrader, at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna. The Phase 1 trial demonstrated ARV-102’s ability to penetrate the blood-brain barrier and significantly degrade LRRK2 protein in both central and peripheral systems, with a favorable safety profile. These findings support further evaluation of ARV-102 in treating neurodegenerative diseases like Parkinson’s disease, with a Phase 1 trial in patients already initiated.

Arvinas and Pfizer Announce Positive Phase 3 Trial Results

On March 11, 2025, Arvinas, Inc. and Pfizer announced positive results from the Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant monotherapy against fulvestrant in patients with ER+/HER2- metastatic breast cancer. The trial met its primary endpoint in the ESR1m population, showing significant improvement in progression-free survival compared to fulvestrant, although it did not achieve statistical significance in the intent-to-treat population. Vepdegestrant was well tolerated, and the trial will continue to assess overall survival as a secondary endpoint. These results may support future regulatory filings and represent a potential advancement in treatment options for patients with advanced breast cancer.